ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
  • Category
  • Region
U.S. (TOLL FREE)
+1 (315) 215-3225
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Biological Vaccines Adjuvants Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-39Y13398
Home | Market Reports | Law & Government| Public Safety
Global Biological Vaccines Adjuvants Market Research Report 2023
BUY CHAPTERS

Global Biological Vaccines Adjuvants Market Research Report 2025

Code: QYRE-Auto-39Y13398
Report
January 2025
Pages:112
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
Dynavax Technologies
Novavax Inc
Agenus
Croda International
SEPPIC
Oz Biosciences
Phibro Animal Health Corporation
Associated British Foods
InvivoGen
Merck KGaA
CSL Limited
Vertellus
Allergy Therapeutics
EuBiologics
Hawaii Biotech
Vaxine Pty Ltd
Creative Diagnostics
Oncovir Inc
Riboxx GmbH
CaPtivatϵ Pharmaceuticals
Pacific GeneTech
LiteVax BV
Mukta Industries
TiterMax USA

Biological Vaccines Adjuvants Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Biological Vaccines Adjuvants Market

Biological Vaccines Adjuvants Market

The global market for Biological Vaccines Adjuvants was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities, and have been used in human vaccines for more than 90 years.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Biological Vaccines Adjuvants, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biological Vaccines Adjuvants.
The Biological Vaccines Adjuvants market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Biological Vaccines Adjuvants market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biological Vaccines Adjuvants manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Biological Vaccines Adjuvants Market Report

Report Metric Details
Report Name Biological Vaccines Adjuvants Market
CAGR 5%
Segment by Type
Segment by Application
  • Human Vaccine
  • Veterinary Vaccine
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GSK, Dynavax Technologies, Novavax, Agenus, Croda International, Seppic, OZ Biosciences, Phibro Animal Health Corporation, Associated British Foods, InvivoGen, Merck KGaA, CSL Limited, Vertellus, Allergy Therapeutics, Riboxx GmbH, CaPtivatϵ Pharmaceuticals, EuBiologics, Pacific GeneTech, Hawaii Biotech, Vaxine Pty Ltd., Creative Diagnostics, LiteVax BV, Mukta Industries, Oncovir, TiterMax USA
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Biological Vaccines Adjuvants manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Biological Vaccines Adjuvants in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Biological Vaccines Adjuvants Market report?

Ans: The main players in the Biological Vaccines Adjuvants Market are GSK, Dynavax Technologies, Novavax, Agenus, Croda International, Seppic, OZ Biosciences, Phibro Animal Health Corporation, Associated British Foods, InvivoGen, Merck KGaA, CSL Limited, Vertellus, Allergy Therapeutics, Riboxx GmbH, CaPtivatϵ Pharmaceuticals, EuBiologics, Pacific GeneTech, Hawaii Biotech, Vaxine Pty Ltd., Creative Diagnostics, LiteVax BV, Mukta Industries, Oncovir, TiterMax USA

What are the Application segmentation covered in the Biological Vaccines Adjuvants Market report?

Ans: The Applications covered in the Biological Vaccines Adjuvants Market report are Human Vaccine, Veterinary Vaccine

What are the Type segmentation covered in the Biological Vaccines Adjuvants Market report?

Ans: The Types covered in the Biological Vaccines Adjuvants Market report are Aluminum Adjuvant, Emulsions Adjuvant, Others

Recommended Reports

Vaccine Markets

Adjuvant & Immune

Cold Chain & Storage

1 Biological Vaccines Adjuvants Market Overview
1.1 Product Definition
1.2 Biological Vaccines Adjuvants by Type
1.2.1 Global Biological Vaccines Adjuvants Market Value Comparison by Type (2024 VS 2031)
1.2.2 Aluminum Adjuvant
1.2.3 Emulsions Adjuvant
1.2.4 Others
1.3 Biological Vaccines Adjuvants by Application
1.3.1 Global Biological Vaccines Adjuvants Market Value by Application (2024 VS 2031)
1.3.2 Human Vaccine
1.3.3 Veterinary Vaccine
1.4 Global Biological Vaccines Adjuvants Market Size Estimates and Forecasts
1.4.1 Global Biological Vaccines Adjuvants Revenue 2020-2031
1.4.2 Global Biological Vaccines Adjuvants Sales 2020-2031
1.4.3 Global Biological Vaccines Adjuvants Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Biological Vaccines Adjuvants Market Competition by Manufacturers
2.1 Global Biological Vaccines Adjuvants Sales Market Share by Manufacturers (2020-2025)
2.2 Global Biological Vaccines Adjuvants Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Biological Vaccines Adjuvants Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Biological Vaccines Adjuvants, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Biological Vaccines Adjuvants, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Biological Vaccines Adjuvants, Product Type & Application
2.7 Global Key Manufacturers of Biological Vaccines Adjuvants, Date of Enter into This Industry
2.8 Global Biological Vaccines Adjuvants Market Competitive Situation and Trends
2.8.1 Global Biological Vaccines Adjuvants Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Biological Vaccines Adjuvants Players Market Share by Revenue
2.8.3 Global Biological Vaccines Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Biological Vaccines Adjuvants Market Scenario by Region
3.1 Global Biological Vaccines Adjuvants Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Biological Vaccines Adjuvants Sales by Region: 2020-2031
3.2.1 Global Biological Vaccines Adjuvants Sales by Region: 2020-2025
3.2.2 Global Biological Vaccines Adjuvants Sales by Region: 2026-2031
3.3 Global Biological Vaccines Adjuvants Revenue by Region: 2020-2031
3.3.1 Global Biological Vaccines Adjuvants Revenue by Region: 2020-2025
3.3.2 Global Biological Vaccines Adjuvants Revenue by Region: 2026-2031
3.4 North America Biological Vaccines Adjuvants Market Facts & Figures by Country
3.4.1 North America Biological Vaccines Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Biological Vaccines Adjuvants Sales by Country (2020-2031)
3.4.3 North America Biological Vaccines Adjuvants Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Biological Vaccines Adjuvants Market Facts & Figures by Country
3.5.1 Europe Biological Vaccines Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Biological Vaccines Adjuvants Sales by Country (2020-2031)
3.5.3 Europe Biological Vaccines Adjuvants Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Biological Vaccines Adjuvants Market Facts & Figures by Region
3.6.1 Asia Pacific Biological Vaccines Adjuvants Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Biological Vaccines Adjuvants Sales by Region (2020-2031)
3.6.3 Asia Pacific Biological Vaccines Adjuvants Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Biological Vaccines Adjuvants Market Facts & Figures by Country
3.7.1 Latin America Biological Vaccines Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Biological Vaccines Adjuvants Sales by Country (2020-2031)
3.7.3 Latin America Biological Vaccines Adjuvants Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Biological Vaccines Adjuvants Market Facts & Figures by Country
3.8.1 Middle East and Africa Biological Vaccines Adjuvants Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Biological Vaccines Adjuvants Sales by Country (2020-2031)
3.8.3 Middle East and Africa Biological Vaccines Adjuvants Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Biological Vaccines Adjuvants Sales by Type (2020-2031)
4.1.1 Global Biological Vaccines Adjuvants Sales by Type (2020-2025)
4.1.2 Global Biological Vaccines Adjuvants Sales by Type (2026-2031)
4.1.3 Global Biological Vaccines Adjuvants Sales Market Share by Type (2020-2031)
4.2 Global Biological Vaccines Adjuvants Revenue by Type (2020-2031)
4.2.1 Global Biological Vaccines Adjuvants Revenue by Type (2020-2025)
4.2.2 Global Biological Vaccines Adjuvants Revenue by Type (2026-2031)
4.2.3 Global Biological Vaccines Adjuvants Revenue Market Share by Type (2020-2031)
4.3 Global Biological Vaccines Adjuvants Price by Type (2020-2031)
5 Segment by Application
5.1 Global Biological Vaccines Adjuvants Sales by Application (2020-2031)
5.1.1 Global Biological Vaccines Adjuvants Sales by Application (2020-2025)
5.1.2 Global Biological Vaccines Adjuvants Sales by Application (2026-2031)
5.1.3 Global Biological Vaccines Adjuvants Sales Market Share by Application (2020-2031)
5.2 Global Biological Vaccines Adjuvants Revenue by Application (2020-2031)
5.2.1 Global Biological Vaccines Adjuvants Revenue by Application (2020-2025)
5.2.2 Global Biological Vaccines Adjuvants Revenue by Application (2026-2031)
5.2.3 Global Biological Vaccines Adjuvants Revenue Market Share by Application (2020-2031)
5.3 Global Biological Vaccines Adjuvants Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Biological Vaccines Adjuvants Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Dynavax Technologies
6.2.1 Dynavax Technologies Company Information
6.2.2 Dynavax Technologies Description and Business Overview
6.2.3 Dynavax Technologies Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Dynavax Technologies Biological Vaccines Adjuvants Product Portfolio
6.2.5 Dynavax Technologies Recent Developments/Updates
6.3 Novavax
6.3.1 Novavax Company Information
6.3.2 Novavax Description and Business Overview
6.3.3 Novavax Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Novavax Biological Vaccines Adjuvants Product Portfolio
6.3.5 Novavax Recent Developments/Updates
6.4 Agenus
6.4.1 Agenus Company Information
6.4.2 Agenus Description and Business Overview
6.4.3 Agenus Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Agenus Biological Vaccines Adjuvants Product Portfolio
6.4.5 Agenus Recent Developments/Updates
6.5 Croda International
6.5.1 Croda International Company Information
6.5.2 Croda International Description and Business Overview
6.5.3 Croda International Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Croda International Biological Vaccines Adjuvants Product Portfolio
6.5.5 Croda International Recent Developments/Updates
6.6 Seppic
6.6.1 Seppic Company Information
6.6.2 Seppic Description and Business Overview
6.6.3 Seppic Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Seppic Biological Vaccines Adjuvants Product Portfolio
6.6.5 Seppic Recent Developments/Updates
6.7 OZ Biosciences
6.7.1 OZ Biosciences Company Information
6.7.2 OZ Biosciences Description and Business Overview
6.7.3 OZ Biosciences Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.7.4 OZ Biosciences Biological Vaccines Adjuvants Product Portfolio
6.7.5 OZ Biosciences Recent Developments/Updates
6.8 Phibro Animal Health Corporation
6.8.1 Phibro Animal Health Corporation Company Information
6.8.2 Phibro Animal Health Corporation Description and Business Overview
6.8.3 Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Phibro Animal Health Corporation Biological Vaccines Adjuvants Product Portfolio
6.8.5 Phibro Animal Health Corporation Recent Developments/Updates
6.9 Associated British Foods
6.9.1 Associated British Foods Company Information
6.9.2 Associated British Foods Description and Business Overview
6.9.3 Associated British Foods Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Associated British Foods Biological Vaccines Adjuvants Product Portfolio
6.9.5 Associated British Foods Recent Developments/Updates
6.10 InvivoGen
6.10.1 InvivoGen Company Information
6.10.2 InvivoGen Description and Business Overview
6.10.3 InvivoGen Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.10.4 InvivoGen Biological Vaccines Adjuvants Product Portfolio
6.10.5 InvivoGen Recent Developments/Updates
6.11 Merck KGaA
6.11.1 Merck KGaA Company Information
6.11.2 Merck KGaA Description and Business Overview
6.11.3 Merck KGaA Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.11.4 Merck KGaA Biological Vaccines Adjuvants Product Portfolio
6.11.5 Merck KGaA Recent Developments/Updates
6.12 CSL Limited
6.12.1 CSL Limited Company Information
6.12.2 CSL Limited Description and Business Overview
6.12.3 CSL Limited Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.12.4 CSL Limited Biological Vaccines Adjuvants Product Portfolio
6.12.5 CSL Limited Recent Developments/Updates
6.13 Vertellus
6.13.1 Vertellus Company Information
6.13.2 Vertellus Description and Business Overview
6.13.3 Vertellus Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Vertellus Biological Vaccines Adjuvants Product Portfolio
6.13.5 Vertellus Recent Developments/Updates
6.14 Allergy Therapeutics
6.14.1 Allergy Therapeutics Company Information
6.14.2 Allergy Therapeutics Description and Business Overview
6.14.3 Allergy Therapeutics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Allergy Therapeutics Biological Vaccines Adjuvants Product Portfolio
6.14.5 Allergy Therapeutics Recent Developments/Updates
6.15 Riboxx GmbH
6.15.1 Riboxx GmbH Company Information
6.15.2 Riboxx GmbH Description and Business Overview
6.15.3 Riboxx GmbH Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Riboxx GmbH Biological Vaccines Adjuvants Product Portfolio
6.15.5 Riboxx GmbH Recent Developments/Updates
6.16 CaPtivatϵ Pharmaceuticals
6.16.1 CaPtivatϵ Pharmaceuticals Company Information
6.16.2 CaPtivatϵ Pharmaceuticals Description and Business Overview
6.16.3 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.16.4 CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product Portfolio
6.16.5 CaPtivatϵ Pharmaceuticals Recent Developments/Updates
6.17 EuBiologics
6.17.1 EuBiologics Company Information
6.17.2 EuBiologics Description and Business Overview
6.17.3 EuBiologics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.17.4 EuBiologics Biological Vaccines Adjuvants Product Portfolio
6.17.5 EuBiologics Recent Developments/Updates
6.18 Pacific GeneTech
6.18.1 Pacific GeneTech Company Information
6.18.2 Pacific GeneTech Description and Business Overview
6.18.3 Pacific GeneTech Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Pacific GeneTech Biological Vaccines Adjuvants Product Portfolio
6.18.5 Pacific GeneTech Recent Developments/Updates
6.19 Hawaii Biotech
6.19.1 Hawaii Biotech Company Information
6.19.2 Hawaii Biotech Description and Business Overview
6.19.3 Hawaii Biotech Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Hawaii Biotech Biological Vaccines Adjuvants Product Portfolio
6.19.5 Hawaii Biotech Recent Developments/Updates
6.20 Vaxine Pty Ltd.
6.20.1 Vaxine Pty Ltd. Company Information
6.20.2 Vaxine Pty Ltd. Description and Business Overview
6.20.3 Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Vaxine Pty Ltd. Biological Vaccines Adjuvants Product Portfolio
6.20.5 Vaxine Pty Ltd. Recent Developments/Updates
6.21 Creative Diagnostics
6.21.1 Creative Diagnostics Company Information
6.21.2 Creative Diagnostics Description and Business Overview
6.21.3 Creative Diagnostics Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Creative Diagnostics Biological Vaccines Adjuvants Product Portfolio
6.21.5 Creative Diagnostics Recent Developments/Updates
6.22 LiteVax BV
6.22.1 LiteVax BV Company Information
6.22.2 LiteVax BV Description and Business Overview
6.22.3 LiteVax BV Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.22.4 LiteVax BV Biological Vaccines Adjuvants Product Portfolio
6.22.5 LiteVax BV Recent Developments/Updates
6.23 Mukta Industries
6.23.1 Mukta Industries Company Information
6.23.2 Mukta Industries Description and Business Overview
6.23.3 Mukta Industries Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Mukta Industries Biological Vaccines Adjuvants Product Portfolio
6.23.5 Mukta Industries Recent Developments/Updates
6.24 Oncovir
6.24.1 Oncovir Company Information
6.24.2 Oncovir Description and Business Overview
6.24.3 Oncovir Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Oncovir Biological Vaccines Adjuvants Product Portfolio
6.24.5 Oncovir Recent Developments/Updates
6.25 TiterMax USA
6.25.1 TiterMax USA Company Information
6.25.2 TiterMax USA Description and Business Overview
6.25.3 TiterMax USA Biological Vaccines Adjuvants Sales, Revenue and Gross Margin (2020-2025)
6.25.4 TiterMax USA Biological Vaccines Adjuvants Product Portfolio
6.25.5 TiterMax USA Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Biological Vaccines Adjuvants Industry Chain Analysis
7.2 Biological Vaccines Adjuvants Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Biological Vaccines Adjuvants Production Mode & Process Analysis
7.4 Biological Vaccines Adjuvants Sales and Marketing
7.4.1 Biological Vaccines Adjuvants Sales Channels
7.4.2 Biological Vaccines Adjuvants Distributors
7.5 Biological Vaccines Adjuvants Customer Analysis
8 Biological Vaccines Adjuvants Market Dynamics
8.1 Biological Vaccines Adjuvants Industry Trends
8.2 Biological Vaccines Adjuvants Market Drivers
8.3 Biological Vaccines Adjuvants Market Challenges
8.4 Biological Vaccines Adjuvants Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GSK
Dynavax Technologies
Novavax Inc
Agenus
Croda International
SEPPIC
Oz Biosciences
Phibro Animal Health Corporation
Associated British Foods
InvivoGen
Merck KGaA
CSL Limited
Vertellus
Allergy Therapeutics
EuBiologics
Hawaii Biotech
Vaxine Pty Ltd
Creative Diagnostics
Oncovir Inc
Riboxx GmbH
CaPtivatϵ Pharmaceuticals
Pacific GeneTech
LiteVax BV
Mukta Industries
TiterMax USA
List of Tables
 Table 1. Global Biological Vaccines Adjuvants Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Biological Vaccines Adjuvants Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Biological Vaccines Adjuvants Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Biological Vaccines Adjuvants Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Biological Vaccines Adjuvants Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Biological Vaccines Adjuvants Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Biological Vaccines Adjuvants Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Biological Vaccines Adjuvants, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Biological Vaccines Adjuvants, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Biological Vaccines Adjuvants, Product Type & Application
 Table 12. Global Key Manufacturers of Biological Vaccines Adjuvants, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Biological Vaccines Adjuvants by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biological Vaccines Adjuvants as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Biological Vaccines Adjuvants Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Biological Vaccines Adjuvants Sales by Region (2020-2025) & (K Units)
 Table 18. Global Biological Vaccines Adjuvants Sales Market Share by Region (2020-2025)
 Table 19. Global Biological Vaccines Adjuvants Sales by Region (2026-2031) & (K Units)
 Table 20. Global Biological Vaccines Adjuvants Sales Market Share by Region (2026-2031)
 Table 21. Global Biological Vaccines Adjuvants Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Biological Vaccines Adjuvants Revenue Market Share by Region (2020-2025)
 Table 23. Global Biological Vaccines Adjuvants Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Biological Vaccines Adjuvants Revenue Market Share by Region (2026-2031)
 Table 25. North America Biological Vaccines Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
 Table 27. North America Biological Vaccines Adjuvants Sales by Country (2026-2031) & (K Units)
 Table 28. North America Biological Vaccines Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Biological Vaccines Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Biological Vaccines Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Biological Vaccines Adjuvants Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Biological Vaccines Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Biological Vaccines Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Biological Vaccines Adjuvants Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Biological Vaccines Adjuvants Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Biological Vaccines Adjuvants Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Biological Vaccines Adjuvants Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Biological Vaccines Adjuvants Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Biological Vaccines Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Biological Vaccines Adjuvants Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Biological Vaccines Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Biological Vaccines Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Biological Vaccines Adjuvants Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Biological Vaccines Adjuvants Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Biological Vaccines Adjuvants Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Biological Vaccines Adjuvants Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Biological Vaccines Adjuvants Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Biological Vaccines Adjuvants Sales (K Units) by Type (2020-2025)
 Table 51. Global Biological Vaccines Adjuvants Sales (K Units) by Type (2026-2031)
 Table 52. Global Biological Vaccines Adjuvants Sales Market Share by Type (2020-2025)
 Table 53. Global Biological Vaccines Adjuvants Sales Market Share by Type (2026-2031)
 Table 54. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Biological Vaccines Adjuvants Revenue Market Share by Type (2020-2025)
 Table 57. Global Biological Vaccines Adjuvants Revenue Market Share by Type (2026-2031)
 Table 58. Global Biological Vaccines Adjuvants Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Biological Vaccines Adjuvants Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Biological Vaccines Adjuvants Sales (K Units) by Application (2020-2025)
 Table 61. Global Biological Vaccines Adjuvants Sales (K Units) by Application (2026-2031)
 Table 62. Global Biological Vaccines Adjuvants Sales Market Share by Application (2020-2025)
 Table 63. Global Biological Vaccines Adjuvants Sales Market Share by Application (2026-2031)
 Table 64. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Biological Vaccines Adjuvants Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Biological Vaccines Adjuvants Revenue Market Share by Application (2020-2025)
 Table 67. Global Biological Vaccines Adjuvants Revenue Market Share by Application (2026-2031)
 Table 68. Global Biological Vaccines Adjuvants Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Biological Vaccines Adjuvants Price (US$/Unit) by Application (2026-2031)
 Table 70. GSK Company Information
 Table 71. GSK Description and Business Overview
 Table 72. GSK Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. GSK Biological Vaccines Adjuvants Product
 Table 74. GSK Recent Developments/Updates
 Table 75. Dynavax Technologies Company Information
 Table 76. Dynavax Technologies Description and Business Overview
 Table 77. Dynavax Technologies Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Dynavax Technologies Biological Vaccines Adjuvants Product
 Table 79. Dynavax Technologies Recent Developments/Updates
 Table 80. Novavax Company Information
 Table 81. Novavax Description and Business Overview
 Table 82. Novavax Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Novavax Biological Vaccines Adjuvants Product
 Table 84. Novavax Recent Developments/Updates
 Table 85. Agenus Company Information
 Table 86. Agenus Description and Business Overview
 Table 87. Agenus Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Agenus Biological Vaccines Adjuvants Product
 Table 89. Agenus Recent Developments/Updates
 Table 90. Croda International Company Information
 Table 91. Croda International Description and Business Overview
 Table 92. Croda International Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Croda International Biological Vaccines Adjuvants Product
 Table 94. Croda International Recent Developments/Updates
 Table 95. Seppic Company Information
 Table 96. Seppic Description and Business Overview
 Table 97. Seppic Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Seppic Biological Vaccines Adjuvants Product
 Table 99. Seppic Recent Developments/Updates
 Table 100. OZ Biosciences Company Information
 Table 101. OZ Biosciences Description and Business Overview
 Table 102. OZ Biosciences Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. OZ Biosciences Biological Vaccines Adjuvants Product
 Table 104. OZ Biosciences Recent Developments/Updates
 Table 105. Phibro Animal Health Corporation Company Information
 Table 106. Phibro Animal Health Corporation Description and Business Overview
 Table 107. Phibro Animal Health Corporation Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Phibro Animal Health Corporation Biological Vaccines Adjuvants Product
 Table 109. Phibro Animal Health Corporation Recent Developments/Updates
 Table 110. Associated British Foods Company Information
 Table 111. Associated British Foods Description and Business Overview
 Table 112. Associated British Foods Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Associated British Foods Biological Vaccines Adjuvants Product
 Table 114. Associated British Foods Recent Developments/Updates
 Table 115. InvivoGen Company Information
 Table 116. InvivoGen Description and Business Overview
 Table 117. InvivoGen Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. InvivoGen Biological Vaccines Adjuvants Product
 Table 119. InvivoGen Recent Developments/Updates
 Table 120. Merck KGaA Company Information
 Table 121. Merck KGaA Description and Business Overview
 Table 122. Merck KGaA Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. Merck KGaA Biological Vaccines Adjuvants Product
 Table 124. Merck KGaA Recent Developments/Updates
 Table 125. CSL Limited Company Information
 Table 126. CSL Limited Description and Business Overview
 Table 127. CSL Limited Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. CSL Limited Biological Vaccines Adjuvants Product
 Table 129. CSL Limited Recent Developments/Updates
 Table 130. Vertellus Company Information
 Table 131. Vertellus Description and Business Overview
 Table 132. Vertellus Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Vertellus Biological Vaccines Adjuvants Product
 Table 134. Vertellus Recent Developments/Updates
 Table 135. Allergy Therapeutics Company Information
 Table 136. Allergy Therapeutics Description and Business Overview
 Table 137. Allergy Therapeutics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Allergy Therapeutics Biological Vaccines Adjuvants Product
 Table 139. Allergy Therapeutics Recent Developments/Updates
 Table 140. Riboxx GmbH Company Information
 Table 141. Riboxx GmbH Description and Business Overview
 Table 142. Riboxx GmbH Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Riboxx GmbH Biological Vaccines Adjuvants Product
 Table 144. Riboxx GmbH Recent Developments/Updates
 Table 145. CaPtivatϵ Pharmaceuticals Company Information
 Table 146. CaPtivatϵ Pharmaceuticals Description and Business Overview
 Table 147. CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. CaPtivatϵ Pharmaceuticals Biological Vaccines Adjuvants Product
 Table 149. CaPtivatϵ Pharmaceuticals Recent Developments/Updates
 Table 150. EuBiologics Company Information
 Table 151. EuBiologics Description and Business Overview
 Table 152. EuBiologics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 153. EuBiologics Biological Vaccines Adjuvants Product
 Table 154. EuBiologics Recent Developments/Updates
 Table 155. Pacific GeneTech Company Information
 Table 156. Pacific GeneTech Description and Business Overview
 Table 157. Pacific GeneTech Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 158. Pacific GeneTech Biological Vaccines Adjuvants Product
 Table 159. Pacific GeneTech Recent Developments/Updates
 Table 160. Hawaii Biotech Company Information
 Table 161. Hawaii Biotech Description and Business Overview
 Table 162. Hawaii Biotech Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 163. Hawaii Biotech Biological Vaccines Adjuvants Product
 Table 164. Hawaii Biotech Recent Developments/Updates
 Table 165. Vaxine Pty Ltd. Company Information
 Table 166. Vaxine Pty Ltd. Description and Business Overview
 Table 167. Vaxine Pty Ltd. Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 168. Vaxine Pty Ltd. Biological Vaccines Adjuvants Product
 Table 169. Vaxine Pty Ltd. Recent Developments/Updates
 Table 170. Creative Diagnostics Company Information
 Table 171. Creative Diagnostics Description and Business Overview
 Table 172. Creative Diagnostics Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 173. Creative Diagnostics Biological Vaccines Adjuvants Product
 Table 174. Creative Diagnostics Recent Developments/Updates
 Table 175. LiteVax BV Company Information
 Table 176. LiteVax BV Description and Business Overview
 Table 177. LiteVax BV Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 178. LiteVax BV Biological Vaccines Adjuvants Product
 Table 179. LiteVax BV Recent Developments/Updates
 Table 180. Mukta Industries Company Information
 Table 181. Mukta Industries Description and Business Overview
 Table 182. Mukta Industries Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 183. Mukta Industries Biological Vaccines Adjuvants Product
 Table 184. Mukta Industries Recent Developments/Updates
 Table 185. Oncovir Company Information
 Table 186. Oncovir Description and Business Overview
 Table 187. Oncovir Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 188. Oncovir Biological Vaccines Adjuvants Product
 Table 189. Oncovir Recent Developments/Updates
 Table 190. TiterMax USA Company Information
 Table 191. TiterMax USA Description and Business Overview
 Table 192. TiterMax USA Biological Vaccines Adjuvants Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 193. TiterMax USA Biological Vaccines Adjuvants Product
 Table 194. TiterMax USA Recent Developments/Updates
 Table 195. Key Raw Materials Lists
 Table 196. Raw Materials Key Suppliers Lists
 Table 197. Biological Vaccines Adjuvants Distributors List
 Table 198. Biological Vaccines Adjuvants Customers List
 Table 199. Biological Vaccines Adjuvants Market Trends
 Table 200. Biological Vaccines Adjuvants Market Drivers
 Table 201. Biological Vaccines Adjuvants Market Challenges
 Table 202. Biological Vaccines Adjuvants Market Restraints
 Table 203. Research Programs/Design for This Report
 Table 204. Key Data Information from Secondary Sources
 Table 205. Key Data Information from Primary Sources
 Table 206. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Biological Vaccines Adjuvants
 Figure 2. Global Biological Vaccines Adjuvants Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Biological Vaccines Adjuvants Market Share by Type: 2024 & 2031
 Figure 4. Aluminum Adjuvant Product Picture
 Figure 5. Emulsions Adjuvant Product Picture
 Figure 6. Others Product Picture
 Figure 7. Global Biological Vaccines Adjuvants Market Value by Application (2020-2031) & (US$ Million)
 Figure 8. Global Biological Vaccines Adjuvants Market Share by Application: 2024 & 2031
 Figure 9. Human Vaccine
 Figure 10. Veterinary Vaccine
 Figure 11. Global Biological Vaccines Adjuvants Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 12. Global Biological Vaccines Adjuvants Market Size (2020-2031) & (US$ Million)
 Figure 13. Global Biological Vaccines Adjuvants Sales (2020-2031) & (K Units)
 Figure 14. Global Biological Vaccines Adjuvants Average Price (US$/Unit) & (2020-2031)
 Figure 15. Biological Vaccines Adjuvants Report Years Considered
 Figure 16. Biological Vaccines Adjuvants Sales Share by Manufacturers in 2024
 Figure 17. Global Biological Vaccines Adjuvants Revenue Share by Manufacturers in 2024
 Figure 18. Global 5 and 10 Largest Biological Vaccines Adjuvants Players: Market Share by Revenue in Biological Vaccines Adjuvants in 2024
 Figure 19. Biological Vaccines Adjuvants Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 20. Global Biological Vaccines Adjuvants Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 21. North America Biological Vaccines Adjuvants Sales Market Share by Country (2020-2031)
 Figure 22. North America Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 23. United States Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Canada Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Europe Biological Vaccines Adjuvants Sales Market Share by Country (2020-2031)
 Figure 26. Europe Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 27. Germany Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. France Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. U.K. Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Italy Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Russia Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Asia Pacific Biological Vaccines Adjuvants Sales Market Share by Region (2020-2031)
 Figure 33. Asia Pacific Biological Vaccines Adjuvants Revenue Market Share by Region (2020-2031)
 Figure 34. China Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. Japan Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. South Korea Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. India Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. Australia Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. China Taiwan Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Indonesia Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Thailand Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Malaysia Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Latin America Biological Vaccines Adjuvants Sales Market Share by Country (2020-2031)
 Figure 44. Latin America Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 45. Mexico Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 46. Brazil Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 47. Argentina Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Middle East and Africa Biological Vaccines Adjuvants Sales Market Share by Country (2020-2031)
 Figure 49. Middle East and Africa Biological Vaccines Adjuvants Revenue Market Share by Country (2020-2031)
 Figure 50. Turkey Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 51. Saudi Arabia Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 52. UAE Biological Vaccines Adjuvants Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Global Sales Market Share of Biological Vaccines Adjuvants by Type (2020-2031)
 Figure 54. Global Revenue Market Share of Biological Vaccines Adjuvants by Type (2020-2031)
 Figure 55. Global Biological Vaccines Adjuvants Price (US$/Unit) by Type (2020-2031)
 Figure 56. Global Sales Market Share of Biological Vaccines Adjuvants by Application (2020-2031)
 Figure 57. Global Revenue Market Share of Biological Vaccines Adjuvants by Application (2020-2031)
 Figure 58. Global Biological Vaccines Adjuvants Price (US$/Unit) by Application (2020-2031)
 Figure 59. Biological Vaccines Adjuvants Value Chain
 Figure 60. Channels of Distribution (Direct Vs Distribution)
 Figure 61. Bottom-up and Top-down Approaches for This Report
 Figure 62. Data Triangulation
 Figure 63. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Veterinary Vaccine Adjuvants Market
Animal Vaccine Adjuvant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Immunostimulatory Adjuvants Market
Global Immune Adjuvant Market Research Report 2024
Human Vaccine Adjuvants Market
Global Mineral based Adjuvants Market Research Report 2024
Global Intramuscular Vaccine Adjuvants Market Research Report 2025
Global Veterinary Biological Vaccines Market Research Report 2025
Global Adjuvant Therapy Market Research Report 2024
Global Human Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030
Global Vaccine Particulate Adjuvants Market Research Report 2025
Global Subcutaneous Vaccine Adjuvants Market Research Report 2025
Global Adjuvanted Influenza Vaccine Market Research Report 2024
Global Human Vaccination Market Research Report 2025
Global Adjuvants in Agriculture Market Research Report 2024
Global Oral Vaccine Adjuvants Market Research Report 2025
Global Travelers Vaccines Market Research Report 2025
Global Travelers Vaccination Market Research Report 2025
Global Biopharmaceutical and Vaccines Market Research Report 2024
Global Oncology Adjuvants Market Insights Forecast to 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions